Literature DB >> 8769899

Secretogranin II: relative amounts and processing to secretoneurin in various rat tissues.

B Leitner1, R Fischer-Colbrie, G Scherzer, H Winkler.   

Abstract

Secretoneurin is a 33-amino-acid peptide produced in vivo from secretogranin II. An antiserum raised against this peptide recognizes both the free peptide and its precursors. By HPLC and radioimmunoassay we characterized the immunoreactive molecules and determined the levels of immunoreactivity in various rat organs. In adrenal medulla and to a lesser degree in the anterior pituitary processing of secretogranin II to secretoneurin was very limited, whereas in all other organs studied (brain, intestine, endocrine pancreas, thyroid gland, and posterior pituitary) a high degree of processing was apparent. Thus, practically all of the immunoreactivity was present as free secretoneurin. This was also true for serum. When the total amount of secretoneurin immunoreactivity was calculated for the various organs, the largest pools in descending order were in the intestine, CNS, anterior pituitary, pancreas, and adrenal gland. This makes it likely that secretoneurin in serum is mainly derived from the intestine. The high degree of processing of secretogranin II in most organs is consistent with the concept that this protein acts as a precursor of a functional peptide, i.e., secretoneurin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769899     DOI: 10.1046/j.1471-4159.1996.66031312.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

Review 1.  Histochemistry and cell biology: the annual review 2010.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2011-01-29       Impact factor: 4.304

Review 2.  Regulation of the biosynthesis of large dense-core vesicles in chromaffin cells and neurons.

Authors:  H Winkler; R Fischer-Colbrie
Journal:  Cell Mol Neurobiol       Date:  1998-04       Impact factor: 5.046

3.  Differential gene expression in the adrenals of normal and anencephalic fetuses and studies focused on the Fras-1-related extracellular matrix protein (FREM2) gene.

Authors:  Christine W Mansfield; Bruce R Carr; Ona M Faye-Petersen; Dongquan Chen; Yewei Xing; William E Rainey; C Richard Parker
Journal:  Reprod Sci       Date:  2011-11       Impact factor: 3.060

4.  Manserin, a secretogranin II-derived peptide, distributes in the rat endocrine pancreas colocalized with islet-cell specific manner.

Authors:  Kaori Tano; Akiko Oyabu; Yasura Tashiro; Naoki Kamada; Naoko Narita; Fumio Nasu; Masaaki Narita
Journal:  Histochem Cell Biol       Date:  2010-05-22       Impact factor: 4.304

5.  Secretoneurin stimulates the production and release of luteinizing hormone in mouse L{beta}T2 gonadotropin cells.

Authors:  E Zhao; Judy R McNeilly; Alan S McNeilly; Reiner Fischer-Colbrie; Ajoy Basak; Jae Young Seong; Vance L Trudeau
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-04-26       Impact factor: 4.310

6.  An ancestral variant of Secretogranin II confers regulation by PHOX2 transcription factors and association with hypertension.

Authors:  Gen Wen; Jennifer Wessel; Weidong Zhou; Georg B Ehret; Fangwen Rao; Mats Stridsberg; Sushil K Mahata; Peter M Gent; Madhusudan Das; Richard S Cooper; Aravinda Chakravarti; Huilin Zhou; Nicholas J Schork; Daniel T O'connor; Bruce A Hamilton
Journal:  Hum Mol Genet       Date:  2007-06-21       Impact factor: 6.150

Review 7.  Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure.

Authors:  Anett H Ottesen; Geir Christensen; Torbjørn Omland; Helge Røsjø
Journal:  Curr Heart Fail Rep       Date:  2017-12

8.  Secretogranin II; a protein increased in the myocardium and circulation in heart failure with cardioprotective properties.

Authors:  Helge Røsjø; Mats Stridsberg; Geir Florholmen; Kåre-Olav Stensløkken; Anett Hellebø Ottesen; Ivar Sjaastad; Cathrine Husberg; Mai Britt Dahl; Erik Øie; William E Louch; Torbjørn Omland; Geir Christensen
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.